TuHURA Biosciences, Inc./NV
TuHURA Biosciences, Inc./NV
TuHURA Biosciences, Inc./NV is a Phase 3 registration-stage immuno-oncology company dedicated to developing innovative technologies that address resistance to cancer immunotherapies, particularly checkpoint inhibitors. Focused on enhancing the effectiveness of cancer treatments, TuHURA leverages its proprietary IFx and Delta receptor technologies to improve patient outcomes in oncology.
Products & Team
IFx-2.0
IFx-2.0 is TuHURA's lead product candidate designed as an innate immune response agonist, specifically formulated to overcome primary resistance to checkpoint inhibitors such as Keytruda.
IFx-2.0 aims to activate the immune system to recognize tumor cells as foreign, effectively improving treatment outcomes for patients who have not adequately responded to current therapies.
Limited effectiveness of current immunotherapy treatments leading to suboptimal patient outcomes.